{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-056481","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.823917+00:00","generated_at":"2026-06-25T23:20:50.237522+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cryoport reports Q1 revenue of $52.3M, net loss $15.4M; FY2022 revenue guidance $260-265M","bullets":["Revenue $52.3M, down 2% YoY; net loss to common holders $15.4M ($0.31 loss per share) vs loss of $5.7M ($0.13) in Q1 2021.","Adjusted EBITDA $1.8M vs $7.2M in prior year; gross margin 42.7% vs 46.1%, impacted by $9.4M fire loss at New Prague plant.","Biopharma/Pharma revenue $43.0M (+1%); Animal Health $6.8M (-24%); Reproductive Medicine $2.5M (+32%). Commercial therapy revenue grew 53.5% to $3.9M.","Full-year 2022 revenue guidance $260-265M (17-19% growth). Cash and short-term investments $600M.","Record 609 clinical trials supported, 81 in Phase 3 (up from 69). Board authorized $100M share repurchase; 306,300 shares repurchased for $8.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-056481","json":"https://secwatch.observer/filing/0001104659-22-056481.json","markdown":"https://secwatch.observer/filing/0001104659-22-056481.md","text":"https://secwatch.observer/filing/0001104659-22-056481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465922056481/0001104659-22-056481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465922056481/tm2214645d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:20:50.237522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}